Mosaic ImmunoEngineering Inc. (CPMV) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Huntington Beach, CA, United States. The current CEO is Steven W. King.
CPMV has IPO date of 2013-01-02, 2 full-time employees, listed on the Other OTC, a market capitalization of $5.03M.
Mosaic ImmunoEngineering Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. It offers MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in mice, dogs, and humans. The company was founded in 2020 and is based in Novato, California.
